Influence of clozapine on platelet serotonin, monoamine oxidase and plasma serotonin levels

Psychiatry Research

Volumn 149, Issue 1-3, 2007, Pages 49-57

  Ertugrul, Aygun ^a   Ucar, Gulberk ^a   Basar, Koray ^a   Demir, Basaran ^a   Yabanoglu, Samiye ^a   Ulug, Berna ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Clozapine; Monoamine oxidase; Platelets; Schizophrenia; Serotonin

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AMISULPRIDE; BIOCHEMICAL MARKER; CLOZAPINE; OLANZAPINE; PIMOZIDE; RISPERIDONE; SEROTONIN;

ADULT; ARTICLE; ATTENTION; CELL LEVEL; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MECHANISM; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MALE; NEUROTRANSMISSION; OUTPATIENT; POSITIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; SEROTONIN BLOOD LEVEL; SEROTONINERGIC SYSTEM; SMOKING; THROMBOCYTE; UNSPECIFIED SIDE EFFECT; VARIANCE;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD PLATELETS; CLOZAPINE; COGNITION DISORDERS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MONOAMINE OXIDASE; NEUROPSYCHOLOGICAL TESTS; QUESTIONNAIRES; SCHIZOPHRENIA, PARANOID; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN; SEVERITY OF ILLNESS INDEX; SMOKING; VERBAL LEARNING; VOCABULARY;

EID: 33846235101     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2005.12.009     Document Type: Article

References (51)

1. Anil A.E., Kivircik B.B., Batur S., Kabakci E., Kitis A., Guven E., Basar K., Turgut T.I., and Arkar H. The Turkish version of the Auditory Consonant Trigram Test as a measure of working memory: a normative study. Clinical Neuropsychologist 17 (2003) 159-169
2. Arora R.C., and Meltzer H.Y. Effects of chlorpromazine on serotonin uptake in blood platelets. Psychiatry Research 9 (1983) 23-28
3. Banki C.M. Alterations of cerebrospinal fluid 5-hydroxyindoleacetic acid, and total blood serotonin content during clozapine treatment. Psychopharmacology (Berlin) 56 (1978) 195-198
4. Benton A.L., and Hamsher K. Multilingual Aphasia Examination: Manual of Instructions (1978), AJA Associates, Iowa City, IA
5. Borcsiczky D., Tekes K., Tarcali{dotless} J., Meszaros Z., Faludi G.M., and Magyar K. Platelet rich plasma serotonin content in patients suffering from different psychiatric disorders. Acta Physiologica Hungarica 84 (1996) 403-404
6. Bridge T.P., Phelps B.H., Cutler N.R., Jeste D.V., and Wyatt R.J. Peripheral catecholamine enzyme function and cognitive impairment of elderly schizophrenics and controls. Journal of the American Geriatrics Society 32 (1984) 259-264
7. Buckman T.D., Kling A., Sutphin M.S., Steinberg A., and Eiduson S. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. Psychiatry Research 31 (1990) 1-14
8. Del Vecchio M., Maj M., D'Ambrosio A., and Kemali D. Low platelet MAO activity in chronic schizophrenics: a long-term effect of neuroleptic treatment?. Psychopharmacology (Berlin) 79 2-3 (1983) 177-179
9. Elman I., Goldstein D.S., Eisenhofer G., Folio J., Malhotra A.K., Adler C.M., Pickar D., and Breier A. Mechanism of peripheral noradrenergic stimulation by clozapine. Neuropsychopharmacology 20 (1999) 29-34
10. Fang J., Yu P.H., Gorrod J.W., and Boulton A.A. Inhibition of monoamine oxidases by haloperidol and its metabolites: pharmacological implications for the chemotherapy of schizophrenia. Psychopharmacology (Berlin) 118 (1995) 206-212
11. Fleischhaker C., Schulz E., and Remschmidt H. Biogenic amines as predictors of response to clozapine treatment in early-onset schizophrenia. Journal of Psychiatric Research 32 (1998) 325-333
12. Garelis E., Gillin J.C., Wyatt R.J., and Neff N. Elevated blood serotonin concentrations in unmedicated chronic schizophrenic patients: a preliminary study. American Journal of Psychiatry 132 (1975) 184-186
13. Gavitrapong P., Mukda S., Turakitwanakan W., Dumrongphol H., Chindaduangratn C., and Sanvarinda Y. Platelet serotonin transporter in schizophrenic patients with and without neuroleptic treatment. Neurochemistry International 41 (2000) 209-216
14. Grace A.A. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Research Reviews 31 (2000) 330-341
15. Heaton R.K. Wisconsin Card Sorting Test Manual (1981), Psychological Assessment Resources, Odessa, FL
16. Heiser P., Hausmann C., Frey J., Geller F., Becker R., Wesemann W., Krieg J.-C., Remschmidt H., and Vedder H. Serotonergic effects of clozapine and its metabolites in hippocampal HT22 cells. Psychiatry Research 112 (2000) 221-229
17. Holt A., Sharman D.F., Baker G.B., and Palcic M.M. A continuous spectrophotometric assay for MAO and related enzymes in tissue homogenates. Analytical Biochemistry 244 (1997) 384-392
18. Ichikawa J., Kuroki T., Dai J., and Meltzer H.Y. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. European Journal of Pharmacology 19 (1998) 163-171
19. Jackman H.L., and Meltzer H.Y. Factors affecting determination of platelet monoamine oxidase activity. Schizophrenia Bulletin 6 (1980) 259-266
20. Jakovljevic M., Muck-Seler D., Pivac N., Ljubicic D., Bujas M., and Dodig G. Seasonal influence on platelet 5-HT levels in patients with recurrent major depression and schizophrenia. Biological Psychiatry 41 (1997) 1028-1034
21. Jernej B., and Cicin-Sain L. Genetic alterations of serotonin uptake kinetics in rat platelets. Biological Psychiatry 29 (1991) 601S
22. Jernej B., Banovic M., Cicin-Sain L., Hranilovic D., Balija M., Oreskovic D., and Folnegovic-Smalc V. Physiologic characteristics of platelet/circulatory serotonin: study on a large human population. Psychiatry Research 94 (2000) 153-162
23. Joseph M.H., Owen F., Baker H.F., and Bourne R.C. Platelet serotonin concentration and monoamine oxidase activity in unmedicated chronic schizophrenic and in schizoaffective patients. Psychological Medicine 7 (1977) 159-162
24. Joyce J.N., Shane A., Lexow N., Winokur A., Casanova M.F., and Kleinman J.E. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8 (1993) 315-336
25. Kaneda Y., Fujii A., and Nagamine I. Platelet serotonin concentrations in medicated schizophrenic patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry 25 (2001) 983-992
26. Kay S.R., Fiszbern A., and Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13 (1987) 261-276
27. Kiive E., Merenakk L., Harro M., and Harro J. Changes in platelet monoamine oxidase activity, cholesterol levels and hyperactive behaviour in adolescents over a period of three years. Neuroscience Letters 384 (2005) 310-315
28. Klinteberg B., Levander S.E., Oreland L., Asberg M., and Schalling D. Neuropsychological correlates of platelet monoamine oxidase (MAO) activity in female and male subjects. Biological Psychology 24 (1987) 237-252
29. Kostakoǧlu E., Batur S., Tiryaki A., and Göǧüş A. Reliability and validity of the Turkish version of the Positive and Negative Syndrome Scale. Türk Psikoloji Dergisi 14 (1999) 23-32
30. Lesch K.P., and Merschdorf U. Impulsivity, aggression, and serotonin: a molecular psychobiological perspective. Behavioral Sciences and the Law 18 (2000) 581-604
31. Lesch K.P., Wolzin B.L., Murphy D.L., and Riederer P. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. Journal of Neurochemistry 60 (1993) 2319-2322
32. Lezak M.D. Neuropsychological Assessment. 3rd edition (1995), Oxford University Press, New York
33. Maj M., Arena F., Galderisi S., Starace F., and Kemali D. Factors associated with decreased platelet MAO activity in chronic schizophrenics. Progress in Neuro-Psychopharmacology & Biological Psychiatry 11 (1987) 79-86
34. Marcolin M.A., and Davis J.M. Platelet monoamine oxidase in schizophrenia: a meta-analysis. Schizophrenia Research 7 (1992) 249-267
35. Meltzer H.Y. Predictors of response to clozapine. Psychiatric Annals 26 (1996) 385-389
36. Meltzer H.Y., and McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 25 (1999) 233-255
37. Meltzer H.Y., Duncavage M.B., Jackman H., Arora R.C., Tricou B.J., and Young M. Effect of neuroleptic drugs on platelet monoamine oxidase in psychiatric patients. American Journal of Psychiatry 139 (1982) 1242-1248
38. Meltzer H.Y., Matsubara S., and Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin-2 pKi values. Journal of Pharmacology and Experimental Therapeutics 251 (1989) 238-246
39. Meszaros Z., Borcsiczky D., Mate M., Tarcali J., Tekes K., and Magyar K. MAO inhibitory side effects of neuroleptics and platelet serotonin content in schizophrenic patients. Journal of Neural Transmission Supplementum 52 (1998) 79-85
40. Muck-Seler D., Jakovljevic M., and Deanovic Z. Platelet serotonin subtypes of schizophrenia and unipolar patients. Psychiatry Research 38 (1991) 105-113
41. Muck-Seler D., Pivac N., Mustapic M., Crncevic Z., Jakovljevic M., and Sagud M. Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women. Psychiatry Research 127 (2004) 217-226
42. Oreland L. Platelet monoamine oxidase, personality and alcoholism: the rise, fall and resurrection. Neurotoxicology 25 (2004) 79-89
43. Oreland L., and Hallman J. The correlation between platelet MAO activity and personality: short review of findings and a discussion on possible mechanisms. In: Yu M., Tipton K., and Boulton A.A. (Eds). Progress in Brain Research vol. 106 (1995), Elsevier Science, Amsterdam 77-82
44. Pivac N., Muck-Seler D., and Jakovljevic M. Platelet 5-HT levels and hypothalamic-pituitary-adrenal axis activity in schizophrenic patients with positive and negative symptoms. Neuropsychobiology 36 (1997) 19-21
45. Schmidt L.G., Dufeu P., Heinz A., Kuhn S., and Rommelspacher H. Serotonergic dysfunction in addiction: effects of alcohol, cigarette smoking and heroin on platelet 5-HT content. Psychiatry Research 72 (1997) 177-185
46. Schulz E., Fleischhaker C., Clement H.W., and Remschmidt H. Blood biogenic amines during clozapine treatment of early onset schizophrenia. Journal of Neural Transmission 104 (1997) 1077-1089
47. Stahl S.M. Platelets as pharmacologic models for the receptors and biochemistry of monoaminergic neurons. In: Longenecker G.L. (Ed). Platelets: Physiology and Pharmacology (1985), Academic Press, New York 307-340
48. Stahl S.M., Woo D.J., Mefford I.N., Berger P.A., and Ciaranello R.D. Hyperserotonemia and platelet serotonin uptake and release in schizophrenia and affective disorders. American Journal of Psychiatry 140 (1983) 26-30
49. van der Heijden F.M.M.A., Tuinier S., Fekkes D., Sijben A.E.S., Kahn R.S., and Verhoeven W.M.A. Atypical antipsychotics and the relevance of glutamate and serotonin. European Neuropsychopharmacology 14 (2004) 259-268
50. Wechsler D. Wechsler Memory Scale-Revised (1987), The Psychological Corporation, New York
51. Zureick J.L., and Meltzer H.Y. Platelet MAO activity in hallucinating and paranoid schizophrenics: a review and meta-analysis. Biological Psychiatry 24 (1988) 63-78